Canada · Delayed Price · Currency is CAD MustGrow Biologics Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw the first TerraSante sales, improved margins, and a narrowed focus after discontinuing NexusBioAg. Manufacturing issues limited Q1 growth, but demand is strong and management expects a stronger second half, with international expansion and capital raises supporting growth.
Fiscal Year 2025
-
2025 sales fell short due to NexusBioAg underperformance, but TerraSante sales surged 377% year-over-year. Focus is now on expanding TerraSante in the U.S. and globally, with improved margins expected in 2026 and cash flow breakeven targeted for 2027.
-
Q3 2025 saw seasonally low sales and no TerraSate revenue due to inventory shortages, but gross margin improved to 22%. Strong demand for TerraSate and new product launches are expected to drive a robust Q4 and a positive outlook for 2026, with break-even targeted next year.